Literature DB >> 10886779

Interleukin-10 produced by the innate immune system masks in vitro evidence of acquired T-cell immunity to E. coli.

C Hessle1, L A Hanson, A E Wold.   

Abstract

Bacteria trigger stimulation of antigen-specific, as well as innate, immune responses. Cytokines and other products of cells belonging to the innate immune system may interfere with the detection of acquired immunity to whole bacteria in vitro. Proliferation and cytokine production by human blood mononuclear cells in response to a whole UV-killed Escherichia coli was compared with the response to commonly used antigen preparations: purified protein derivative (PPD), Candida albicans and influenza proteins. E. coli induced a weaker proliferative response with later onset than did the other antigens, and production of interferon (IFN)-gamma comparable with that in response to C. albicans and influenza vaccine, but lower than that induced by PPD. Both proliferation and IFN-gamma production were abolished by removal of CD4 cells or blocking of HLA-D, but not CD1 antigen-presenting molecules. Purified lipopolysaccharide (LPS) induced neither proliferation nor IFN-gamma production. None of the antigen preparations stimulated interleukin (IL)-4 production but, in contrast to the other antigens, whole E. coli, as well as purified O6 LPS, induced large quantities of IL-10. IL-10 production was independent of CD4 cells or HLA-D molecules. Blocking of IL-10 by neutralizing antibodies increased both E. coli-induced proliferation and IFN-gamma production markedly. Conversely, the addition of whole E. coli or LPS to cultures stimulated with other antigens (C. albicans or Staphylococcus aureus) down-regulated proliferative and IFN-gamma responses, an effect which was at least partly IL-10 dependent. The results indicate a substantial T-cell memory to commensal E. coli, but suggest that the evidence of such memory, e.g. proliferation and IFN-gamma production, is effectively prevented by IL-10 and perhaps other factors produced by monocytes in response to bacteria. Thus, the innate immune responses must be taken into account when acquired immune responses to microbes are measured.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886779     DOI: 10.1046/j.1365-3083.2000.00741.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Langerhans cells from human oral epithelium are more effective at stimulating allogeneic T cells in vitro than Langerhans cells from skin.

Authors:  B Hasséus; M Jontell; G Bergenholtz; U I Dahlgren
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 2.  Food allergy: separating the science from the mythology.

Authors:  Per Brandtzaeg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07       Impact factor: 46.802

3.  Monocyte-derived interleukin-10 depresses the Bordetella pertussis- specific gamma interferon response in vaccinated infants.

Authors:  V Dirix; V Verscheure; T Goetghebuer; M Hainaut; A S Debrie; C Locht; F Mascart
Journal:  Clin Vaccine Immunol       Date:  2009-10-21

4.  Relationship of relapsing hip prosthesis infection by Staphylococcus aureus with gamma interferon deficiency.

Authors:  Amélie Honstettre; Jean-Louis Mège; Gérard Lina; Jean-Manuel Aubaniac; Michel Drancourt
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

5.  Neonatal gut colonization by Bifidobacterium is associated with higher childhood cytokine responses.

Authors:  Hardis Rabe; Anna-Carin Lundell; Fei Sjöberg; Annika Ljung; Anna Strömbeck; Monica Gio-Batta; Cristina Maglio; Inger Nordström; Kerstin Andersson; Intawat Nookaew; Agnes E Wold; Ingegerd Adlerberth; Anna Rudin
Journal:  Gut Microbes       Date:  2020-11-09

6.  Characterization of humoral and cellular immune responses elicited by meningococcal carriage.

Authors:  K Robinson; K R Neal; C Howard; J Stockton; K Atkinson; E Scarth; J Moran; A Robins; I Todd; E Kaczmarski; S Gray; I Muscat; R Slack; D A A Ala'Aldeen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.